{"id":"placebo-for-estradiol-norethindrone-acetate","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo formulations are used in randomized controlled trials to establish the efficacy and safety of active pharmaceutical agents by providing an inert control arm. In this case, the placebo matches the appearance and administration route of the active Estradiol/Norethindrone Acetate combination but contains no hormonal components, allowing researchers to isolate the true therapeutic effects of the hormone replacement therapy from psychological or expectancy effects.","oneSentence":"This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:07.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management"}]},"trialDetails":[{"nctId":"NCT03271489","phase":"PHASE3","title":"Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-13","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":478},{"nctId":"NCT03213457","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-07-07","conditions":"Endometriosis","enrollment":681},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT01656434","phase":"PHASE3","title":"Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2012-11-02","conditions":"Contraception","enrollment":3173},{"nctId":"NCT05620355","phase":"PHASE3","title":"Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.","status":"UNKNOWN","sponsor":"Bio Genuine (Shanghai) Biotech Co., Ltd.","startDate":"2022-12-16","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":312},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT02925494","phase":"PHASE3","title":"An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-14","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":433},{"nctId":"NCT02691494","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-03","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":378},{"nctId":"NCT01441635","phase":"PHASE2","title":"Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-09-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":271},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638},{"nctId":"NCT01817530","phase":"PHASE2","title":"Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-08","conditions":"Heavy Uterine Bleeding, Uterine Fibroids","enrollment":571},{"nctId":"NCT02654054","phase":"PHASE3","title":"Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-22","conditions":"Uterine Fibroids, Heavy Menstrual Bleeding","enrollment":413},{"nctId":"NCT01466114","phase":"PHASE2","title":"Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":"Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis","enrollment":64},{"nctId":"NCT00600106","phase":"NA","title":"Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"1999-12","conditions":"Myocardial Ischemia","enrollment":37},{"nctId":"NCT02693002","phase":"PHASE4","title":"Estrogen Diastolic Heart Failure","status":"TERMINATED","sponsor":"Gretchen Wells","startDate":"2016-02","conditions":"Menopause","enrollment":4},{"nctId":"NCT00184795","phase":"PHASE3","title":"Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-05-28","conditions":"Menopause, Menopausal Vasomotor Symptoms","enrollment":576},{"nctId":"NCT01465022","phase":"NA","title":"Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2005-01","conditions":"Breast Feeding, Contraception","enrollment":197},{"nctId":"NCT02292732","phase":"PHASE1","title":"A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Cancer","enrollment":""},{"nctId":"NCT00474851","phase":"PHASE2","title":"The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2007-08","conditions":"Endometriosis","enrollment":53},{"nctId":"NCT01953809","phase":"PHASE1","title":"A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-08","conditions":"Infections, Bacterial","enrollment":""},{"nctId":"NCT01631981","phase":"PHASE2","title":"PGL2001 Proof of Concept Study in Symptomatic Endometriosis","status":"COMPLETED","sponsor":"PregLem SA","startDate":"2012-06","conditions":"Endometriosis","enrollment":162},{"nctId":"NCT00999479","phase":"NA","title":"Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation","status":"WITHDRAWN","sponsor":"University of Oklahoma","startDate":"2009-10","conditions":"Endometrioma","enrollment":""},{"nctId":"NCT00932321","phase":"PHASE3","title":"Study of Safety and Efficacy of an Oral Contraceptive","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-01","conditions":"Prevention of Pregnancy","enrollment":938},{"nctId":"NCT00212342","phase":"PHASE3","title":"Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2004-12","conditions":"Dysmenorrhea","enrollment":100},{"nctId":"NCT01040845","phase":"PHASE1","title":"A Pharmacokinetic Study of Colchicine With an Oral Contraceptive","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2007-08","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT00877097","phase":"NA","title":"Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"1996-07","conditions":"Osteoporosis","enrollment":167}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Estradiol/Norethindrone Acetate","genericName":"Placebo for Estradiol/Norethindrone Acetate","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate. Used for Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}